---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-294892"
form_type: "8-K"
ticker: "APLS"
cik: "0001492422"
company_name: "Apellis Pharmaceuticals, Inc."
filed_at: "2023-12-14T23:59:59+00:00"
generated_at: "2026-06-07T12:45:51.333390+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Apellis receives negative trend vote on EU MAA for pegcetacoplan; expects CHMP negative opinion in Jan 2024

## Summary
- CHMP negative trend vote on MAA for intravitreal pegcetacoplan for geographic atrophy (GA) after Dec 13 oral explanation.
- Apellis expects CHMP to adopt negative opinion at Jan 22-25, 2024 meeting.
- Company plans to appeal and seek re-examination of the opinion.
- Pegcetacoplan is for GA secondary to age-related macular degeneration.

## SEC filing metadata
- accession: 0001193125-23-294892
- form_type: 8-K
- ticker: APLS
- cik: 0001492422
- company_name: Apellis Pharmaceuticals, Inc.
- filed_at: 2023-12-14T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1492422/000119312523294892/0001193125-23-294892-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1492422/000119312523294892/d863487d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-294892
- JSON: https://secwatch.observer/filing/0001193125-23-294892.json
- Plain text: https://secwatch.observer/filing/0001193125-23-294892.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.